Blackstone and TPG Close $18.3B Hologic Take-Private

Blackstone and TPG have officially closed their $18.3 billion acquisition of Hologic, the women's health technology company announced Sunday, completing one of the largest healthcare buyouts of 2026 and signaling that private equity's appetite for mega-cap medical device assets hasn't disappeared — it's just gotten pickier.

The deal, first announced in late 2025, takes the Marlborough, Massachusetts-based maker of breast imaging systems, diagnostic instruments, and surgical products private at a time when public healthcare companies face mounting pressure from pricing regulations, supply chain volatility, and skeptical investors who've soured on medical device valuations. Hologic shareholders receive $85 per share in cash, representing a 28% premium to where the stock traded before acquisition rumors surfaced.

What makes this transaction notable isn't just its size — though at $18.3 billion in enterprise value, it ranks among the top five healthcare buyouts globally this year. It's the bet that two of private equity's most sophisticated healthcare investors are making: that Hologic's core franchises in women's health, diagnostics, and surgical devices can deliver stronger returns outside the quarterly earnings cycle, despite headwinds that have made public market investors queasy.

The firms aren't saying much about their plans yet. The press release is corporate-speak light on strategy. But the decision to partner — Blackstone and TPG will hold roughly equal stakes — suggests the scale and complexity of modernizing Hologic's portfolio required splitting both the capital commitment and operational risk.

Mega-cap healthcare buyouts don't happen quickly, and this one faced the scrutiny you'd expect for a transaction of this size in a politically sensitive sector. Regulatory clearance came from the Federal Trade Commission in late March, following a review process that examined whether the take-private would reduce competition in breast imaging or molecular diagnostics markets where Hologic holds dominant positions.

The answer, ultimately, was no — Hologic competes with publicly traded giants like GE HealthCare, Siemens Healthineers, and Roche in fragmented markets where private ownership doesn't fundamentally alter competitive dynamics. But the months-long review highlights a reality for healthcare PE in 2026: even deals that don't involve horizontal integration are getting longer, harder looks from regulators sensitive to consolidation in medical technology.

Financing the deal also required navigating a debt market that's become less forgiving since the low-rate era ended. The firms secured roughly $8 billion in debt financing — a manageable but not insignificant leverage ratio for a company with Hologic's cash flow profile. Credit investors demanded higher spreads than comparable deals would have received two years ago, reflecting concern about healthcare reimbursement trends and the sector's exposure to policy shifts.

Still, the deal got done. That alone says something about both Hologic's underlying fundamentals and the sponsors' conviction that they can operate the business better than the public market would reward.

Hologic isn't a speculative growth bet. It's a cash-generating medical device incumbent with leading positions in three core verticals: breast health (mammography systems and related imaging), diagnostics (molecular testing, blood screening), and surgical products (minimally invasive gynecological devices). The company generated roughly $4.1 billion in revenue in its most recent fiscal year, with operating margins in the high-20% range — respectable but not exceptional by medtech standards.

The crown jewel is the breast imaging franchise. Hologic's 3D mammography systems are installed in thousands of hospitals and imaging centers across the U.S., creating a high-margin installed base that generates recurring revenue from service contracts and consumable sales. That's the kind of annuity-like business model private equity loves — predictable, defensible, and not easily disrupted by new entrants.

But the public market had started to price Hologic as if that growth story was over. Shares traded at a discount to peers despite the installed base moat, weighed down by concerns about Medicare reimbursement pressure, slower capital equipment cycles in hospitals post-pandemic, and competition from AI-enabled diagnostic tools that could eventually commoditize traditional imaging workflows.

Private equity's thesis is straightforward: those are real headwinds, but they're also solvable problems if you're willing to invest in R&D, expand internationally, and optimize operations without the pressure of hitting quarterly earnings targets. The public market wasn't giving Hologic credit for its international growth potential or its pipeline of next-generation diagnostics. Blackstone and TPG are betting they can unlock both.

The diagnostic business is where the most upside — and risk — lives. Hologic's molecular diagnostics platform competes in sexually transmitted infection testing, respiratory panels, and women's health screening. It's a high-growth category, but also one facing intense competition from larger players like Roche and Abbott, and pricing pressure as tests become more commoditized.

One area where Hologic has underperformed relative to its potential is international expansion. Roughly 70% of revenue still comes from the United States, despite the fact that breast cancer screening rates in Europe and parts of Asia are rising and healthcare systems are investing in advanced imaging. Private equity ownership could accelerate commercial expansion in regions where Hologic has been underpenetrated — assuming the firms are willing to fund the upfront investment required to build out sales and service infrastructure.

This deal doesn't exist in a vacuum. It's part of a broader pattern of private equity re-engaging with large-scale healthcare buyouts after a few years of relative caution. For much of 2023 and 2024, healthcare PE activity tilted toward mid-market deals, healthcare services roll-ups, and venture-stage biotech — lower-risk plays in a higher-rate environment where debt was expensive and exits were uncertain.

But 2026 has seen a resurgence of mega-cap healthcare M&A, driven by three factors: public market valuations that still haven't fully recovered from the 2022-2023 correction, a growing pool of dry powder at the largest PE firms, and the realization that certain healthcare assets — particularly those with durable market positions and exposure to aging demographics — are genuinely scarce.

Hologic fits that profile. Women's health is a category with secular tailwinds: increasing screening rates globally, rising awareness of conditions like breast cancer and osteoporosis, and growing demand for minimally invasive surgical options. The company also benefits from demographic trends — an aging female population in developed markets drives more imaging procedures, diagnostic tests, and surgical interventions.

The sponsors are betting those tailwinds are durable enough to outweigh near-term headwinds like reimbursement pressure and capital equipment budget constraints. Whether they're right depends largely on execution — something private equity likes to think it does better than public company management teams constrained by shareholder activism and quarterly earnings pressure.

But here's the thing: Hologic wasn't a broken company. It was profitable, growing modestly, and held defensible market positions. The public market just wasn't rewarding it. That's different from a classic PE turnaround, and it raises a question the industry doesn't always want to answer: if the business was fundamentally sound, why couldn't it succeed as a public company?

Public healthcare investors have become allergic to anything that looks like revenue volatility or margin pressure, even when it's cyclical or temporary. Hologic's capital equipment sales — the big-ticket 3D mammography systems — are inherently lumpy. Hospitals don't replace imaging systems on a predictable schedule. They delay purchases when budgets tighten, then buy in clusters when reimbursement improves or new technology becomes available.

That's a normal part of the medical device cycle, but public investors punish it. Every quarter that capital equipment sales miss expectations, the stock gets hammered. Private ownership eliminates that dynamic. Blackstone and TPG can take a five-to-seven-year view, smooth out the lumpiness, and invest in R&D or sales infrastructure without worrying about what analysts will say on the next earnings call.

The financing structure for this deal matters because it shapes what the sponsors can — and can't — do with Hologic over the next few years. With roughly $8 billion in debt on the balance sheet, the company will carry a leverage ratio in the mid-4x range based on trailing EBITDA. That's aggressive but not reckless for a company with Hologic's cash flow characteristics.

The debt load means two things: first, the firms will prioritize margin expansion and cash flow optimization early in the hold period to service the debt and demonstrate financial progress to lenders. Second, they'll be disciplined about M&A — transformational add-on acquisitions are possible, but only if they're immediately accretive and don't stretch the balance sheet further.

Exit timing is the bigger question mark. Blackstone and TPG will hold this asset for at least four to five years, likely longer. The most obvious exit path is a re-IPO, taking the company public again once they've repositioned the portfolio, expanded internationally, and delivered the kind of growth and margin story that makes public investors excited. But that only works if public market appetite for medical device IPOs recovers — not a given in 2026.

A strategic sale is the alternative. Hologic's franchises could be attractive to larger medtech incumbents looking to fill portfolio gaps, but regulatory scrutiny of horizontal mergers in healthcare has only intensified. Any deal involving a major competitor like GE HealthCare or Siemens would face antitrust review. A financial sponsor-to-sponsor sale is possible but would require finding another PE firm willing to pay a premium for a business that's already been optimized.

Blackstone and TPG's limited partners will expect a gross multiple of at least 2.0x to 2.5x on invested capital, which translates to an IRR in the high teens to low twenties over a five-to-seven-year hold. Hitting that target requires growing Hologic's EBITDA from roughly $1.2 billion today to north of $1.6 billion by exit, while also expanding margins and reducing leverage.

The path to that outcome runs through product innovation, international expansion, and operational efficiency — all things the firms will claim they're better positioned to deliver than public company management. The counterargument is that Hologic's management team was already focused on those priorities. Private equity's edge, if it exists, is removing the distraction of managing a stock price and letting the operators focus on building the business.

One thing the press release doesn't address — and won't — is what private ownership means for Hologic's roughly 6,000 employees and its R&D pipeline. Private equity has a complicated reputation in healthcare for a reason. Some firms treat portfolio companies as long-term platforms, investing in talent and innovation. Others optimize aggressively for near-term cash flow, cutting costs that don't immediately hit the bottom line.

Blackstone and TPG both have track records in healthcare that lean toward the former. They've backed companies like Luminor Dental, Team Health, and Envision Healthcare with mixed results, but they've also funded R&D expansions and international growth at portfolio companies when the business case is solid. The question is whether Hologic's innovation pipeline — particularly in next-generation diagnostics and AI-enabled imaging — gets the capital it needs to compete, or whether those projects get deprioritized in favor of milking the installed base.

The company's diagnostic and imaging products require ongoing investment to stay competitive. Competitors are rolling out AI-powered screening tools, cloud-based diagnostic platforms, and lower-cost alternatives to traditional imaging systems. If Hologic underinvests in R&D during the PE hold period, it could emerge in worse competitive shape than when it went private — a risk that public market investors won't be around to worry about, but that the next buyer or IPO investors certainly will.

R&D spend at Hologic has hovered around 7% of revenue in recent years — in line with medical device peers but below the levels of more innovation-driven companies. Whether that increases, decreases, or stays flat under private equity ownership will be one of the early signals of the sponsors' strategy.

Employees should expect efficiency reviews. That's standard. Whether those reviews lead to workforce reductions or strategic reallocations depends on how much operational bloat the firms find and how aggressive they are about cutting it. Healthcare services PE deals often result in significant headcount reductions. Medical device deals tend to be less severe, but not immune.

Step back, and the Hologic deal is part of a decade-long trend that should worry anyone who thinks public markets are the best allocators of capital in healthcare. Over the past ten years, an increasing share of valuable healthcare assets — hospitals, physician groups, diagnostic labs, medical device companies, and even some pharma-adjacent businesses — have migrated from public to private ownership.

That's not inherently bad. Private capital can be patient capital, and some businesses genuinely perform better outside the glare of quarterly earnings. But it also means less transparency, less regulatory oversight, and fewer mechanisms for public accountability when things go wrong. Private equity-owned hospitals and healthcare services companies have faced scrutiny for billing practices, staffing cuts, and reduced care quality. Medical device and diagnostics companies have more insulation from those dynamics, but they're not immune.

The question isn't whether Blackstone and TPG will be good stewards of Hologic — they have every financial incentive to be. The question is whether the continued migration of healthcare assets to private ownership is creating a system where the most important health technologies are controlled by a small number of firms optimizing for financial returns rather than public health outcomes.

That's a tension the private equity industry doesn't spend much time addressing, and it's not going away. If anything, it's getting sharper as mega-cap healthcare buyouts come back into vogue.

The Hologic deal is closed, but the story is just starting. Over the next 12 to 18 months, a few things will signal whether this transaction was a smart bet or an overpay at the peak of a cycle.

First, watch for management changes. If Blackstone and TPG bring in a new CEO or replace senior executives, it's a sign they think the operational strategy needs a reset. If they keep the existing team in place, it suggests they view this more as a financial engineering play — take a solid business private, optimize the capital structure, and ride secular tailwinds.

Second, track international expansion. If Hologic announces new distribution partnerships, regulatory approvals in major markets outside the U.S., or acquisitions of regional imaging or diagnostics players, it means the sponsors are serious about the international growth thesis. If international revenue as a percentage of total revenue stays flat, the growth story is mostly talk.

Third, monitor R&D. Product launches, clinical trial announcements, and FDA clearances for next-generation devices will indicate whether innovation is getting the capital it needs. If the product pipeline thins or launch timelines stretch, it's a red flag that short-term cash flow optimization is taking priority.